QDEL QuidelOrtho (QDEL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0001906324
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
149
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $0 priced
QuidelOrtho insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for QuidelOrtho Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 24, 2025.
- The trade is 32.8% of the 10,290 shares held after it.
- 2 other insiders bought within 30 days.
- 149 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Busky Joseph M. bought about $79.7K of QDEL on Feb 13, 2026; 2 other insiders bought within 30 days and 149 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 36.0% of the 27,775 shares held after it.
- 2 other insiders bought within 30 days.
- 149 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Strobeck Matthew bought about $239.6K of QDEL on Feb 13, 2026; 2 other insiders bought within 30 days and 149 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 19, 2025.
- +0.0% median (+0.0% mean) 90-day return after 2 previous buys.
- The trade is 26.3% of the 40,073 shares held after it.
- 2 other insiders bought within 30 days.
- 149 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Blaser Brian J. bought about $248.6K of QDEL on Feb 13, 2026; 2 other insiders bought within 30 days and 149 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.0% of the 15,021 shares held after it.
- 4 other insiders bought within 30 days.
- 149 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RHOADS ANN D bought about $21.2K of QDEL on Dec 10, 2025; 4 other insiders bought within 30 days and 149 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.1% of the 11,876 shares held after it.
- 4 other insiders bought within 30 days.
- 149 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wilkins Joseph D Jr. bought about $10.3K of QDEL on Nov 26, 2025; 4 other insiders bought within 30 days and 149 funds added in the latest 13F quarter.119 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
149 funds bought in last quarter
more than 81% of Pharma & Biotech
Revenue
-1.9% year over year
below 59% of Pharma & Biotech
Margin
-41.5% net margin
more than 52% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
24.4% of the float short (float per yahoo 2026-10-26) · 11.0 days to cover · settled 2026-09-30
more than 96% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch QDEL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-53.8%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns QDEL: institutional holders (13F)
13F holdings, latest reported quarter
11,202,523 sh
$196.2M
7,363,696 sh
$129.0M
6,625,000 sh
$116.0M
4,135,464 sh
$72.4M
3,534,619 sh
$62.1M
Congress trades in QDEL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
QDEL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
QDEL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Paradigm Micro-Cap Fund
$9.1M position · as of 2026-06-30
5.0%
Paradigm Value Fund
$1.8M position · as of 2026-06-30
3.2%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$3.2M position · as of 2026-06-30
2.1%
Paradigm Select Fund
$3.3M position · as of 2026-06-30
1.2%
SBH SMALL CAP VALUE FUND
$5.1M position · as of 2026-06-30
1.1%
BALLAST SMALL/MID CAP ETF
$1.8M position · as of 2026-06-30
1.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Douglas C.Bryant
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$6.8M
$4.0M
$2.9M
-59%
-18%
2022
$12.9M
$6.7M
$3.8M
-52%
-23%
2021
$5.5M
$3.1M
$2.5M
-25%
-4%
2020
$7.2M
$27.9M
$2.2M
+139%
+30%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 149 funds added last quarter. Each figure is a federal filing, dated the day it went public.
QDEL financials
Revenue growth
-1.9%
XBRL, annual
Net margin
-41.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.7B
four quarters, 2025-06-30 to 2026-06-28
Revenue, TTM QDEL
| FY Dec 2025 | $2.7B |
| FY Dec 2024 | $2.8B |
| FY Dec 2023 | $3.0B |
| FY Jan 2023 | $3.3B |
| FY Jan 2022 | n/a |
| Jun 2026 | $630.9M |
| Mar 2026 | $619.8M |
| Dec 2025 | $723.6M |
| Sep 2025 | $699.9M |
| Jun 2025 | $613.9M |
| Mar 2025 | $692.8M |
| Dec 2024 | $707.8M |
| Sep 2024 | $727.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-39.2%
net income over revenue, 2025-06-30 to 2026-06-28
Net margin, TTM QDEL
| FY Dec 2025 | -41.5% |
| FY Dec 2024 | -73.7% |
| FY Dec 2023 | -0.3% |
| FY Jan 2023 | +16.8% |
| FY Jan 2022 | n/a |
| Jun 2026 | -14.7% |
| Mar 2026 | -14.8% |
| Dec 2025 | -18.1% |
| Sep 2025 | -104.7% |
| Jun 2025 | -41.6% |
| Mar 2025 | -1.8% |
| Dec 2024 | -25.2% |
| Sep 2024 | -2.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$211.2M
operating cash flow minus capex, 2025-06-30 to 2026-06-28
Free cash flow, TTM QDEL
| FY Dec 2025 | -$83.0M |
| FY Dec 2024 | -$112.1M |
| FY Dec 2023 | $70.9M |
| FY Jan 2023 | $744.4M |
| FY Jan 2022 | n/a |
| Jun 2026 | -$136.1M |
| Mar 2026 | -$67.0M |
| Dec 2025 | $86.6M |
| Sep 2025 | -$94.7M |
| Jun 2025 | -$84.3M |
| Mar 2025 | $9.4M |
| Dec 2024 | $16.5M |
| Sep 2024 | $71.4M |
At each fiscal year end
Single quarter
Debt to equity
1.63x
long-term 2026-06-28 plus current 2026-06-28; equity 2026-06-28
Debt to equity QDEL
| FY Dec 2025 | 1.50x |
| FY Dec 2024 | 0.95x |
| FY Dec 2023 | 0.51x |
| FY Jan 2023 | 0.58x |
| FY Jan 2022 | 0.00x |
| Jun 2026 | 1.63x |
| Mar 2026 | 1.45x |
| Dec 2025 | 1.50x |
| Sep 2025 | 1.31x |
| Jun 2025 | 0.93x |
| Mar 2025 | 0.83x |
| Dec 2024 | 0.95x |
| Sep 2024 | 0.80x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.02x
TTM operating cash flow over long-term 2026-06-28 plus current 2026-06-28
Cash flow to debt QDEL
| FY Dec 2025 | 0.04x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.11x |
| FY Jan 2023 | 0.31x |
| FY Jan 2022 | n/a |
| Jun 2026 | -0.02x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.04x |
| Sep 2025 | 0.01x |
| Jun 2025 | 0.08x |
| Mar 2025 | 0.06x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-45.9%
TTM net income over average of 2025-06-29 and 2026-06-28
Return on equity QDEL
| FY Dec 2025 | -46.1% |
| FY Dec 2024 | -51.4% |
| FY Dec 2023 | -0.2% |
| FY Jan 2023 | +16.0% |
| FY Jan 2022 | +43.2% |
| Jun 2026 | -45.9% |
| Mar 2026 | -49.9% |
| Dec 2025 | -46.1% |
| Sep 2025 | -45.2% |
| Jun 2025 | -15.6% |
| Mar 2025 | -11.4% |
| Dec 2024 | -51.4% |
| Sep 2024 | -45.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-17.3%
TTM net income over average of 2025-06-29 and 2026-06-28
Return on assets QDEL
| FY Dec 2025 | -18.6% |
| FY Dec 2024 | -27.4% |
| FY Dec 2023 | -0.1% |
| FY Jan 2023 | +9.7% |
| FY Jan 2022 | +29.0% |
| Jun 2026 | -17.3% |
| Mar 2026 | -20.0% |
| Dec 2025 | -18.6% |
| Sep 2025 | -18.9% |
| Jun 2025 | -7.1% |
| Mar 2025 | -5.4% |
| Dec 2024 | -27.4% |
| Sep 2024 | -24.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital QDEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | +11.0% |
| FY Jan 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-16.6%
operating income (EBIT proxy) over average of 2025-06-29 and 2026-06-28 minus current liabilities
Return on capital employed QDEL
| FY Dec 2025 | -18.0% |
| FY Dec 2024 | -29.8% |
| FY Dec 2023 | +1.8% |
| FY Jan 2023 | +16.9% |
| FY Jan 2022 | n/a |
| Jun 2026 | -16.6% |
| Mar 2026 | -19.5% |
| Dec 2025 | -18.0% |
| Sep 2025 | -17.9% |
| Jun 2025 | -4.2% |
| Mar 2025 | -3.0% |
| Dec 2024 | -29.8% |
| Sep 2024 | -27.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing QDEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | 7.17x |
| FY Jan 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$3.7B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2026-06-28 plus current 2026-06-28, minus cash 2026-06-28
Enterprise value QDEL
| FY Dec 2025 | $4.7B |
| FY Dec 2024 | $5.7B |
| FY Dec 2023 | $7.4B |
| FY Jan 2023 | $8.2B |
| FY Jan 2022 | n/a |
| Jun 2026 | $3.7B |
| Mar 2026 | $3.6B |
| Dec 2025 | $4.7B |
| Sep 2025 | $4.5B |
| Jun 2025 | $4.4B |
| Mar 2025 | $4.7B |
| Dec 2024 | $5.7B |
| Sep 2024 | $5.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-22.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield QDEL
| FY Dec 2025 | -4.2% |
| FY Dec 2024 | -3.8% |
| FY Dec 2023 | +1.4% |
| FY Jan 2023 | +13.2% |
| FY Jan 2022 | n/a |
| Jun 2026 | -22.5% |
| Mar 2026 | -15.8% |
| Dec 2025 | -4.2% |
| Sep 2025 | -8.0% |
| Jun 2025 | +0.7% |
| Mar 2025 | -1.5% |
| Dec 2024 | -3.8% |
| Sep 2024 | -3.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing QDEL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| FY Jan 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2023-01 | |
|---|---|---|---|---|
| Revenue | $2.7B | $2.8B | $3.0B | $3.3B |
| Operating income | -$919.2M | -$2.0B | $139.1M | $843.7M |
| Net income | -$1.1B | -$2.1B | -$10.1M | $548.7M |
| EPS (diluted) | -16.69 | -30.54 | -0.15 | 9.56 |
| Operating cash flow | $105.2M | $83.0M | $280.2M | $885.3M |
| Cash | $169.8M | $98.3M | $118.9M | $292.9M |
| Long-term debt | $2.7B | $2.5B | $2.4B | $2.6B |
| Buybacks | $0 | $0 | $7.2M | $74.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
QDEL Stock Sonar score 5/7 axes
Find similar shapesCompareQDEL ranks highest on institutional and government (81st percentile) and profitability (67th), and lowest on risk and compliance (15th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
